ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > 0.50 CAD by Years End

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBettyon May 24, 2022 9:25am

169 Views

Post# 34703272

RE:RE:RE:RE:RE:0.50 CAD by Years End

You can count on one hand the number of Boston investors that have 125/430 million of the float. Throw in some insiders and a few others probably widely held. Supply side not the issue, years of not meeting corporate objectives failing to produce any credible news is the issue. Don't need the Nasdaq to create demand.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market